SAB Biotherapeutics, Inc. (SABSW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SAB Biotherapeutics, Inc. (SABSW) trades at $0.028. SAB Biotherapeutics, Inc. is a biopharmaceutical company focused on developing immunotherapies. Their diverse pipeline targets infectious diseases, autoimmune disorders, and oncology, utilizing their proprietary DiversitAb™ platform. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SABSW: SABSW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SABSW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SABSW: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bullish.
How is this calculated? →SAB Biotherapeutics, Inc. (SABSW) Healthcare & Pipeline Overview
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted polyclonal antibody therapeutics using its DiversitAb™ platform. The company focuses on addressing unmet needs in infectious diseases, autoimmune diseases, and oncology, operating within the competitive biotechnology sector.
What Is the Investment Thesis for SABSW?
SAB Biotherapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's DiversitAb™ platform offers a novel approach to antibody therapeutics, potentially providing advantages over traditional monoclonal antibodies in certain disease areas. Key value drivers include the successful clinical development and commercialization of SAB-142, SAB-176, and SAB-301. The company's P/E ratio of 5.92 suggests undervaluation, but this must be weighed against the inherent risks of drug development. Upcoming clinical trial results for its lead candidates represent significant catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
SABSW Key Highlights
SAB Biotherapeutics operates in the biotechnology industry, which is characterized by high growth potential and significant investment in research and development.
- The company's DiversitAb™ platform offers a unique approach to polyclonal antibody therapeutics, potentially providing advantages over traditional monoclonal antibodies.
- SAB Biotherapeutics' pipeline includes product candidates targeting infectious diseases, autoimmune diseases, and oncology, diversifying its risk profile.
- The company's headquarters in Sioux Falls, South Dakota, and additional office in Cambridge, Massachusetts, provide access to talent and resources.
- SAB Biotherapeutics has a beta of 0.61, indicating lower volatility compared to the overall market.
Who Are SABSW's Competitors?
SABSW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DRMA Dermata Therapeutics, Inc. | $1.38 | -6.12% | — | |
| KTTA Pasithea Therapeutics Corp. | $0.47 | -4.08% | $15.7M | — |
| NUWE Nuwellis, Inc. | $1.12 | -4.27% | — | |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SABSW's Key Strengths?
Proprietary DiversitAb™ platform.
- Diverse pipeline of product candidates.
- Experienced management team.
- Strategic partnerships with leading research institutions.
What Are SABSW's Weaknesses?
Limited financial resources.
- Dependence on successful clinical trial outcomes.
- Competition from established pharmaceutical companies.
- Regulatory hurdles and approval timelines.
What Could Drive SABSW Stock Higher?
Clinical trial results for SAB-142 in Type 1 diabetes expected in Q4 2026.
- Clinical trial results for SAB-176 in seasonal influenza expected in Q1 2027.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Continued advancements in the DiversitAb™ platform.
What Are the Key Risks for SABSW?
Financial-distress signal — its Altman Z-Score of -0.34 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for lead product candidates.
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies and biosimilars.
- Dependence on securing additional funding to support research and development.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for SABSW?
- Expansion into New Therapeutic Areas: SAB Biotherapeutics has the opportunity to leverage its DiversitAb™ platform to develop immunotherapies for additional diseases beyond its current pipeline. This could include expanding into new oncology indications, autoimmune disorders, or infectious diseases with high unmet medical needs. The market for novel immunotherapies is substantial and growing, offering significant revenue potential for SAB. Timeline: 2027-2030.
- Strategic Partnerships and Collaborations: SAB Biotherapeutics can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to funding, expertise, and distribution channels, enhancing the company's growth prospects. The pharmaceutical industry is increasingly relying on collaborations to access innovative technologies and expand their pipelines. Timeline: Ongoing.
- Government Funding and Grants: SAB Biotherapeutics can actively seek government funding and grants to support its research and development efforts. Government agencies such as the National Institutes of Health (NIH) and the Department of Defense (DOD) provide significant funding for biotechnology research, particularly in areas such as infectious diseases and biodefense. Securing these grants can reduce the company's financial risk and accelerate its development programs. Timeline: Ongoing.
- Geographic Expansion: SAB Biotherapeutics can expand its geographic reach by establishing partnerships or subsidiaries in key international markets. This would allow the company to access new patient populations and generate additional revenue streams. The global market for immunotherapies is growing rapidly, particularly in emerging markets. Timeline: 2028-2032.
- Advancements in DiversitAb™ Platform: SAB Biotherapeutics can continue to invest in research and development to further enhance its DiversitAb™ platform. This could include improving the efficiency of antibody production, expanding the range of target antigens, or developing new delivery methods. These advancements would strengthen the company's competitive advantage and create new opportunities for product development. Timeline: Ongoing.
What Are SABSW's Competitive Advantages?
- Proprietary DiversitAb™ platform for polyclonal antibody production.
- Patent protection for its lead product candidates.
- Expertise in developing immunotherapies.
- Established relationships with key opinion leaders in the medical community.
What Does SABSW Do?
SAB Biotherapeutics, Inc., established in 2014, is a biopharmaceutical company dedicated to developing novel immunotherapies. The company's core technology, the DiversitAb™ platform, leverages transgenic cattle to produce human polyclonal antibodies. These antibodies are designed to target a wide range of diseases, including infectious diseases like influenza and MERS-CoV, autoimmune diseases such as Type 1 diabetes, and various oncology indications. SAB Biotherapeutics operates from its headquarters in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts, facilitating collaboration and access to talent in key biotech hubs. SAB's lead product candidates include SAB-142, an anti-thymocyte globulin for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). The company aims to address critical unmet medical needs by harnessing the power of polyclonal antibody therapeutics.
What Products and Services Does SABSW Offer?
- Develops immunotherapies for infectious diseases.
- Creates treatments for autoimmune diseases.
- Researches and develops therapies for oncology.
- Utilizes the DiversitAb™ platform to produce human polyclonal antibodies.
- Offers SAB-142 anti-thymocyte globulin for Type 1 diabetes.
- Develops SAB-176 for seasonal influenza.
- Creates SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV).
How Does SABSW Make Money?
- Develops and patents novel immunotherapies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties.
- Secures government grants and funding for research and development.
What Industry Does SABSW Operate In?
SAB Biotherapeutics operates within the biotechnology industry, a sector characterized by rapid innovation and high growth potential. The competitive landscape includes established pharmaceutical companies and smaller biotech firms focused on developing novel therapeutics. SAB Biotherapeutics differentiates itself through its DiversitAb™ platform, which offers a unique approach to polyclonal antibody production. Key industry trends include the increasing prevalence of chronic diseases, the growing demand for personalized medicine, and the rising adoption of biologics.
Who Are SABSW's Key Customers?
- Patients suffering from infectious diseases.
- Individuals with autoimmune disorders.
- Oncology patients.
- Pharmaceutical companies seeking novel therapeutics.
- Government agencies focused on biodefense.
Company Profile
SAB Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Samuel J. Reich. SABSW has traded publicly since 2021.
Financial Health
SAB Biotherapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.34 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project SAB Biotherapeutics, Inc. revenue of about $333K for fiscal 2026, with EPS near $-1.05. The estimate reflects 5 contributing analysts.
SABSW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming developments.
- Community sentiment has shifted positively, with discussions highlighting the potential of SAB Biotherapeutics' unique therapeutic approaches.
- Recent partnerships and collaborations have sparked interest, positioning the company favorably within the biotherapeutics landscape.
- Increased media coverage has raised awareness about SAB's innovative pipeline, attracting attention from both retail and institutional investors.
Bear Case
- Concerns about regulatory hurdles persist, as the biopharmaceutical landscape can be unpredictable and fraught with challenges.
- Some community discussions reflect skepticism regarding the commercialization timeline for SAB's products, suggesting potential delays ahead.
- Market perception remains cautious, with some analysts questioning the scalability of SAB's technology in a competitive market.
- Recent volatility in biotech stocks has led to increased risk aversion among investors, dampening enthusiasm for companies like SAB Biotherapeutics.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
SABSW Latest News
No recent news available for SABSW.
SABSW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SABSW.
Price Targets
Wall Street price target analysis for SABSW.
SABSW MoonshotScore
What does this score mean?
The MoonshotScore rates SABSW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Samuel J. Reich
CEO
Samuel J. Reich serves as the CEO of SAB Biotherapeutics, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various biotech companies, where he focused on strategic planning, business development, and clinical operations. Reich has a proven track record of successfully advancing drug candidates through clinical development and securing partnerships with major pharmaceutical companies. His expertise spans multiple therapeutic areas, including infectious diseases, autoimmune disorders, and oncology.
Track Record: Under Samuel J. Reich's leadership, SAB Biotherapeutics has made significant progress in advancing its pipeline of immunotherapies. Key achievements include the development of the DiversitAb™ platform, the initiation of clinical trials for SAB-142, SAB-176, and SAB-301, and the establishment of strategic partnerships with leading research institutions. Reich has also been instrumental in securing government funding and grants to support the company's research and development efforts.
Common Questions About SABSW (Healthcare)
What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc. is a biopharmaceutical company focused on developing novel immunotherapies using its proprietary DiversitAb™ platform. This platform leverages transgenic cattle to produce human polyclonal antibodies, which are designed to target a wide range of diseases, including infectious diseases, autoimmune disorders, and oncology.
What do analysts say about SABSW stock?
Analyst coverage of SABSW is currently limited, reflecting its status as a smaller, clinical-stage biotechnology company. Key valuation metrics to consider include the company's market capitalization, cash runway, and the potential market size for its lead product candidates. Growth considerations center on the successful completion of clinical trials and the potential for regulatory approvals.
What are the main risks for SABSW?
The main risks for SABSW are typical of a clinical-stage biotechnology company. These include the risk of clinical trial failures, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining marketing approvals also pose a significant risk. Competition from established pharmaceutical companies and biosimilars could limit the market potential for SAB's product candidates.
What are the key factors to evaluate for SABSW?
Evaluate SABSW on fundamentals, analyst consensus, and risk factors. SAB Biotherapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does SABSW data refresh on this page?
SABSW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SABSW's recent stock price performance?
SAB Biotherapeutics, Inc. (SABSW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary DiversitAb™ platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SABSW overvalued or undervalued right now?
SAB Biotherapeutics, Inc. (SABSW) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SABSW before investing?
Before investing in SAB Biotherapeutics, Inc. (SABSW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.